/PRNewswire/ Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer.
/PRNewswire/ Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations (CRO), it has decided.
/PRNewswire/ South Korea s biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry.